Evidence map›Paper›PMID 36896796›Full record

ArticleESC heart failure2023

Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality.

Angiza Shahim, Marion Hourqueig, Lars H Lund, Gianluigi Savarese, Emmanuel Oger, Ashwin Venkateshvaran, Lina Benson, Jean-Claude Daubert, Cecilia Linde, Erwan Donal and 1 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Angiza ShahimDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4574-149X
Marion HourqueigDépartement de Cardiologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Lars H LundDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Gianluigi SavareseDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Emmanuel OgerDépartement de Pharmacologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Ashwin VenkateshvaranDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Lina BensonDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Jean-Claude DaubertFaculté de Médecine, Universitaire de Rennes 1, Rennes, France.
Cecilia LindeDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Erwan DonalFaculté de Médecine, Universitaire de Rennes 1, Rennes, France.
Camilla HageDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska University Hospital · SECentre Hospitalier Universitaire de Rennes · FRKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHeart failure (HF) with preserved ejection fraction (HFpEF) is associated with cardiovascular (CV) and non-CV events, but long-term risk is poorly studied. We assessed incidence and predictors of the long-term CV and non-CV events. METHODS AND

resultsPatients presenting with acute HF, EF ≥ 45%, and N-terminal pro-brain natriuretic peptide > 300 ng/L were enrolled in the Karolinska-Rennes study in 2007-11 and were reassessed after 4-8 weeks in a stable state. Long-term follow-up was conducted in 2018. The Fine-Gray sub-distribution hazard regression was used to detect predictors of CV and non-CV deaths, investigated separately from baseline acute presentation (demographic data only) and from the 4-8 week outpatient visit (including echocardiographic data). Of 539 patients enrolled [median age 78 (interquartile range: 72-84) years; 52% female], 397 patients were available for the long-term follow-up. Over a median follow-up time from acute presentation of 5.4 (2.1-7.9) years, 269 (68%) patients died, 128 (47%) from CV and 120 (45%) from non-CV causes. Incidence rates per 1000 patient-years were 62 [95% confidence interval (CI) 52-74] for CV and 58 (95% CI 48-69) for non-CV death. Higher age and coronary artery disease (CAD) were independent predictors of CV death, and anaemia, stroke, kidney disease, and lower body mass index (BMI) and sodium concentrations of non-CV death. From the stable 4-8 week visit, anaemia, CAD, and tricuspid regurgitation (>3.1 m/s) were independent predictors of CV death, and higher age of non-CV death.

conclusionsIn patients with acute decompensated HFpEF, over 5 years of follow-up, nearly two-thirds of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both outcomes. [Correction added on 24 March 2023, after first online publication: In the first sentence of the Conclusions, 'two-thirds' has been inserted before 'of patients died...' in this version.].

Indexed as

Heart FailureKidney DiseasesStrokeTricuspid Valve InsufficiencyAgedFemaleHumansMalePrognosisSodiumStroke VolumeSodiumCardiovascular mortalityDiastolic heart failureHeart failure with preserved ejection fractionNon-cardiovascular mortalityOutcomePrognosis

Identifiers

PMID36896796
PMCPMC10192235
OpenAlexW4323812609

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.